Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma × capmatinib × Clear all

Phase

Phase 4 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Sarcoma 1 Neoplasm Metastasis 1 Carcinoma 1

Interventions

Carboplatin 17 Cisplatin 14 Paclitaxel 12 Pemetrexed 11 pembrolizumab 9 Gemcitabine 7 Docetaxel 6 Sorafenib 5 osimertinib 4 durvalumab 4 130-nm albumin-bound paclitaxel 4 padeliporfin 3 cabozantinib 3 atezolizumab 3 Taxes 3 Radiotherapy 3 Mitomycin 3 Magnetic Resonance Spectroscopy 3 Cetuximab 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 trifluridine tipiracil drug combination 2 regorafenib 2 olaparib 2 Sunitinib 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Nivolumab 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04816214 2024-03-05

GEOMETRY-E

Novartis

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡